News

Parametric's Custom Active Platform Expands with New Strategies

Parametric's Custom Active Platform Expands with New Strategies

Parametric’s Custom Active Solution Expands Significantly

In a significant enhancement to its offerings, Parametric Portfolio Associates LLC, a part of Morgan Stanley Investment Management, recently revealed exciting growth within its Custom Active platform. This innovative platform specializes in tax optimization solutions tailored for asset managers, and now incorporates more than 35 new strategies. Collaborations with high-profile partners such as Columbia Threadneedle Investments, Lord Abbett & Co. LLC, PGIM, Polen Capital, and Voya Investment Management have played a crucial role in this expansion.

New Partnerships Strengthening the Offering

The integration of these partnerships enhances the Custom Active solution, which allows asset managers to fine-tune their strategies while maintaining tax efficiency. Thomas Lee, Co-President and Chief Investment Officer at Parametric, noted the excitement surrounding this growth as it reflects the increasing demand for customization in investment strategies aimed at meeting complex investor needs. Parametric’s vast experience in providing long-lasting solutions enabled this growth to cater to investors requiring tailored approaches.

Strategies from Both New and Existing Partners

Within the newly revamped platform, Parametric now showcases over 45 active equity strategies. Among these, 11 strategies come from the latest partners, while existing collaborations with Capital Group and Lazard Asset Management contribute an additional 10 strategies. Furthermore, MSIM's investment teams have developed 13 innovative strategies, including those from Atlanta Capital and Calvert.

Unique Features of Custom Active Solution

All strategies in the Custom Active solution are expertly managed by Parametric itself, ensuring a high level of oversight and tax management. This platform resonates well with a diverse range of individual investors and financial advisors, as expressed by Matt Witkos, Head of North America Intermediary Sales at MSIM. The demand for tax efficiency has driven asset managers to enhance their offerings beyond traditional structures, demonstrating a marked shift in the investment landscape.

Customization Capabilities for Investors

Parametric’s Custom Active solution is designed to address complex investment needs through a separately managed account (SMA) framework, optimized for tax management. Investors benefit from further customization opportunities, such as sector and industry screens, along with client-directed gain and risk budgets. These options empower asset managers to craft strategies that align closely with their clients' specific investment goals.

Overview of Parametric

For over three decades, Parametric has been a trailblazer in delivering custom investment solutions geared towards helping advisors, institutions, and consultants achieve their long-term financial aspirations. The firm enables investors to gain efficient market exposure while tackling implementation challenges. In addition to its extensive range of tax-managed model strategies, Parametric also provides systematic alpha strategies to complement core holdings.

About Morgan Stanley Investment Management

Morgan Stanley Investment Management boasts over 1,400 investment professionals globally and has a staggering $1.7 trillion in assets under management. The firm remains committed to delivering exceptional, long-term investment performance and estate management solutions for a diverse clientele, including institutions, governments, and individual investors. For those seeking more information about the comprehensive suite of investment management solutions, Morgan Stanley Investment Management offers an extensive overview on its platform.

Frequently Asked Questions

What is Parametric’s Custom Active solution?

Parametric’s Custom Active solution is a platform designed for tax-optimized asset management, allowing customization of investment strategies.

Who are the main partners involved in the expansion?

The expansion involves partnerships with Columbia Threadneedle, Lord Abbett, PGIM, Polen Capital, and Voya Investment Management.

How many strategies does the platform now offer?

The Custom Active platform now offers more than 45 active equity strategies from various investment teams.

What are the benefits of the Custom Active solution?

Benefits include tax efficiency, customization options, and access to expertly managed strategies adapted to investor needs.

How can investors access these strategies?

These strategies are made available to retail investors via select intermediaries and registered investment advisers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Kinetic Seas Incorporated Secures First Customer Success

Updated Category News Views 56

Kinetic Seas Incorporated Secures First Customer and Financial Growth Kinetic Seas Incorporated (OTC: ECGR) is excited to announce the signing of its first customer, along with impressive revenue results for the second quarter. This milestone marks a significant step forward as the company pursues its goals in the artificial intelligence sector. Second Quarter Revenue...

Continue Reading
Webinar Guide for Veterans to Maximize Benefits Offered by CCK Law

Updated Category News Views 134

Helping Veterans Discover VA Benefits with a Free Webinar Chisholm Chisholm & Kilpatrick LTD (CCK Law), a preeminent veterans disability law firm, is excited to introduce a free, on-demand webinar aimed at assisting veterans in uncovering valuable VA benefits that many may be unaware of. Insights from the Experts The webinar, dubbed "Biggest Benefits Veterans Overlook,"...

Continue Reading
Tech Market Shifts: Navigating Opportunities and Challenges Ahead

Updated Category News Views 161

Understanding Recent Market Dynamics In recent weeks, global markets have been experiencing heightened volatility, particularly in the technology sector. With various significant events unfolding—including new political leadership in Japan and shifts in economic data—investors are carefully analyzing these developments to navigate potential risks and opportunities....

Continue Reading
Michael Beland Joins Advance Auto Parts as Chief Accounting Officer

Updated Category News Views 720

Welcome Michael Beland to Advance Auto Parts Advance Auto Parts, Inc. (NYSE: AAP), known for its significant role in the automotive aftermarket, recently made an important announcement regarding its executive leadership. The company has appointed Michael Beland as the new senior vice president, controller, and chief accounting officer, marking a pivotal addition to their...

Continue Reading
Recall Movement Against Governor Newsom Gains Momentum

Updated Category News Views 276

Recall Movement Gains Traction in California In an unprecedented move, SavingCalifornia.vote has taken a significant step to initiate a recall against Governor Gavin Newsom. This initiative marks a pivotal moment in California's political landscape. The organization is gathering support and will soon submit the official notice of intent to recall, alongside the necessary...

Continue Reading